Skip to content
Home/Companies/Biotech/Caprion Biosciences

Caprion Biosciences

Biotech·Canada·Exited 2019·Held 3yr
Entry
2016
Hold
3yr
Exit
2019

Who owns Caprion Biosciences?

Caprion Biosciences was owned by GHO Capital through GHO Capital Fund I LP (2015 vintage) from 2016 to 2019, exited via Secondary.

Buyer identity available on Pro.

Hand-verified · updated 2026-07-07

GHO Capital
Investor
GHO Capital
GHO Capital Fund I LP · 2015 · Buyout

Key facts

HQCanada
SectorBiotech
StatusAcquired
Exit Type
Secondary
Buyer
MOIC
–
Exit Year
2019

More from GHO Capital Fund I LP

Other portfolio companies in the same fund.

BioAgilytix
Exited 2021
BiotechUS· 2018
to
Linimed-Fazmed
Active
HealthcareGermany· 2018
VISUfarma
VISUfarma
Exited 2026
PharmaUK· 2016
to
DNA Diagnostics Center
Exited 2021
HealthcareUS· 2015
to
Quotient Clinical
Active
HealthcareUK· 2015
Quotient Sciences
Exited 2019
PharmaUK· 2015
to

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Caprion Biosciences

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Caprion Biosciences?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Caprion Biosciences.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue